help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-1465
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolak, M.
Right arrow Articles by Fisher, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolak, M.
Right arrow Articles by Fisher, R. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
Hazardous Substances DB
*METFORMIN HYDROCHLORIDE
Related Collections
Right arrow Diabetes and Insulin
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 2 720-724
Copyright © 2007 by The Endocrine Society


BRIEF REPORT

Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes

Maria Kolak, Hannele Yki-Järvinen, Katja Kannisto, Mirja Tiikkainen, Anders Hamsten, Per Eriksson and Rachel M. Fisher

Atherosclerosis Research Unit (M.K., K.K., A.H., P.E., R.M.F.), King Gustaf V Research Institute, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden; Department of Medicine (H.Y.-J., M.T.), Division of Diabetes, University of Helsinki, 00029 Helsinki, Finland; and Minerva Institute for Medical Research (H.Y.-J.), 00290 Helsinki, Finland

Address all correspondence and requests for reprints to: Rachel M. Fisher, Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Institutet, Karolinska University Hospital M1:01, 171 76 Stockholm, Sweden. E-mail: rachel.fisher{at}ki.se.

Objective: The aim of this study was to compare effects of therapeutic doses of rosiglitazone and metformin on expression of 50 genes in human adipose tissue in vivo.

Methods: Twenty patients with diet-treated type 2 diabetes (13 women, seven men) were randomized to receive either rosiglitazone (n = 9; 8 mg/d) or metformin (n = 11; 2 g/d) for 16 wk. Subcutaneous adipose tissue biopsies were performed before and after treatment. Expression of 50 genes, previously shown to be altered by thiazolidinediones in experimental models, was quantified by real-time PCR and normalized to two housekeeping genes.

Results: Rosiglitazone, but not metformin, treatment increased expression of genes involved in triacylglycerol storage [e.g. stearyl-CoA desaturase (3.2-fold), CD36 (1.8-fold)], structural genes [e.g. {alpha}-1 type-1 procollagen (1.7-fold) and GLUT4 (1.5-fold)], and decreased expression of inflammation-related genes [e.g. IL-6 (0.6-fold), chemokine (C-C motif) ligand 3 (0.4-fold)], 11ß-hydroxysteroid dehydrogenase 1 (0.6-fold), and resistin (0.3-fold) (all P < 0.05).

Conclusions: These results suggest that the insulin-sensitizing action of rosiglitazone involves remodeling of human adipose tissue to reduce inflammation and promote lipid storage. Furthermore, we show some important differences between thiazolidinedione action in human adipose tissue and experimental models.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D.-E. Lee, S. Kehlenbrink, H. Lee, M. Hawkins, and J. S. Yudkin
Getting the message across: mechanisms of physiological cross talk by adipose tissue
Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1210 - E1229.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. A. Permana, W. Zhang, M. Wabitsch, P. Fischer-Posovszky, W. C. Duckworth, and P. D. Reaven
Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages
Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1076 - E1084.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Yao-Borengasser, N. Rassouli, V. Varma, A. M. Bodles, N. Rasouli, R. Unal, B. Phanavanh, G. Ranganathan, R. E. McGehee Jr., and P. A. Kern
Stearoyl-Coenzyme A Desaturase 1 Gene Expression Increases after Pioglitazone Treatment and Is Associated with Peroxisomal Proliferator-Activated Receptor-{gamma} Responsiveness
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4431 - 4439.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Oberbach, S. Lehmann, K. Kirsch, J. Krist, M. Sonnabend, A. Linke, A. Tonjes, M. Stumvoll, M. Bluher, and P. Kovacs
Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene
Eur. J. Endocrinol., August 1, 2008; 159(2): 129 - 136.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
G. J. Hausman, S. P. Poulos, T. D. Pringle, and M. J. Azain
The influence of thiazolidinediones on adipogenesis in vitro and in vivo: Potential modifiers of intramuscular adipose tissue deposition in meat animals
J Anim Sci, April 1, 2008; 86(14_suppl): E236 - E243.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society